Here's how this drugmaker proved the bears wrong, and why that means it's worth investing $1,500 in today. Read More: Earn up ...

Argonne National Laboratory will use its world-leading capabilities in artificial intelligence (AI) and high performance computing to research novel ways to fight cancer and transform vaccine ...

The UChicago Medicine team will be led by Odunsi as co-principal investigator and includes Christopher Weber, Savas Tay, and ...

AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Geoff Meacham ...

Terence Flynn, an analyst from Morgan Stanley, reiterated the Buy rating on AbbVie (ABBV – Research Report). The associated price target ...

Scientists at the Johns Hopkins Kimmel Cancer Center have identified 16 genes that breast cancer cells use to survive in the bloodstream after they've escaped the low-oxygen regions of a tumor.

This was fueled by strength from medications Skyrizi and Rinvoq in the immunology portfolio, Venclexta in oncology, and Botox Therapeutic and Vraylar in neuroscience. AbbVie’s adjusted earnings ...

EvolveImmune CEO Stephen Bloch said: "This collaboration with AbbVie, a global leader in oncology, offers tremendous validation of the EVOLVE platform and the dedicated and creative work of the ...

Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer NORTH CHICAGO, Ill.

The partnership will focus on creating multispecific biologics targeting various oncology indications. Credit: afotostock via Shutterstock. AbbVie has entered into a partnership and option-to-license ...

(RTTNews) - AbbVie (ABBV) and EvolveImmune Therapeutics announced a collaboration and option-to-license agreement to develop multispecific biologics for multiple targets in oncology. The ...